The New England journal of medicine
-
Multicenter Study Clinical Trial
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase. ⋯ Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed.
-
Letter Case Reports
Combined aortic surgery and implantation of a left ventricular assist device.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia.
Cardiac arrest outside the hospital is common and has a poor outcome. Studies in laboratory animals suggest that hypothermia induced shortly after the restoration of spontaneous circulation may improve neurologic outcome, but there have been no conclusive studies in humans. In a randomized, controlled trial, we compared the effects of moderate hypothermia and normothermia in patients who remained unconscious after resuscitation from out-of-hospital cardiac arrest. ⋯ Our preliminary observations suggest that treatment with moderate hypothermia appears to improve outcomes in patients with coma after resuscitation from out-of-hospital cardiac arrest.